NEW YORK (GenomeWeb) – 23andMe announced today that it has partnered with Celmatix, a personalized medicine company focused on fertility and women's health, to develop and validate biomarkers to diagnose and treat infertility.

Celmatix will contribute data from its discovery and annotation of more than 5,200 genetic biomarkers related to fertility, and 23andMe will add its genetic database and research community knowledge to the collaboration.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.